Development of a Focused Oligonucleotide-Array Comparative Genomic Hybridization Chip for Clinical Diagnosis of Genomic Imbalance
Open Access
- 1 December 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (12), 2051-2059
- https://doi.org/10.1373/clinchem.2007.090290
Abstract
Background: Submicroscopic genomic imbalance underlies well-defined microdeletion and microduplication syndromes and contributes to general developmental disorders such as mental retardation and autism. Array comparative genomic hybridization (CGH) complements routine cytogenetic methods such as karyotyping and fluorescence in situ hybridization (FISH) for the detection of genomic imbalance. Oligonucleotide arrays in particular offer advantages in ease of manufacturing, but standard arrays for single-nucleotide polymorphism genotyping or linkage analysis offer variable coverage in clinically relevant regions. We report the design and validation of a focused oligonucleotide-array CGH assay for clinical laboratory diagnosis of genomic imbalance. Methods: We selected >10 000 60-mer oligonucleotide features from Agilent’s eArray probe library to interrogate all subtelomeric and pericentromeric regions and 95 additional clinically relevant regions for a total of 179 loci. Sensitivity and specificity were measured for 105 patient samples, including 51 with known genomic-imbalance events, as detected by bacterial artificial chromosome–based array CGH, FISH, or multiplex ligation-dependent probe amplification. Results: Focused array CGH detected all known regions of genomic imbalance in 51 validation samples with 100% concordance and an excellent signal-to-noise ratio. The mean SD among log2 ratios of all noncontrol features without copy number alteration was 0.062 (median, 0.055). Clinical testing of another 211 samples from individuals with developmental delay, unexplained mental retardation, dysmorphic features, or multiple congenital anomalies revealed genomic imbalance in 25 samples (11.9%). Conclusions: This focused oligonucleotide-array CGH assay, a flexible, robust method for clinically diagnosing genetic disorders associated with genomic imbalance, offers appreciable advantages over currently available platforms.Keywords
Funding Information
- National Institutes of Health (NS24279)
- National Institute of Neurological Disorders and Stroke (R37 NS35129)
- Children’s Tumor Foundation
This publication has 22 references indexed in Scilit:
- Application of Array-Based Comparative Genomic Hybridization to Clinical DiagnosticsThe Journal of Molecular Diagnostics, 2006
- Oligonucleotide Microarray Analysis of Genomic Imbalance in Children with Mental RetardationAmerican Journal of Human Genetics, 2006
- BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH)Nucleic Acids Research, 2006
- Diagnostic Genome Profiling in Mental RetardationAmerican Journal of Human Genetics, 2005
- Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH)Journal of Medical Genetics, 2005
- Array-based comparative genomic hybridization in clinical diagnosisExpert Review of Molecular Diagnostics, 2005
- Use of targeted array‐based CGH for the clinical diagnosis of chromosomal imbalance: Is less more?American Journal of Medical Genetics Part A, 2005
- Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic featuresJournal of Medical Genetics, 2004
- Practice parameter: Evaluation of the child with global developmental delay [RETIRED]Neurology, 2003
- High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarraysNature Genetics, 1998